stockrowLegend Biotech Corporation Sponsored ADR
LEGN Healthcare Biotechnology
Legend Biotech Corporation Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 64.0% from fiscal 2024.
- Revenue
- +51.9%
- EPS
- +126.1%
- Free cash flow
- −26.8%
- Total debt
- −49.6%
Quarter to June 2026, against a year earlier
Follow LEGN
Alert me
Legend Biotech Corporation Sponsored ADR (LEGN) P/S ratio
As of 6 November 2026, Legend Biotech Corporation Sponsored ADR (LEGN) trades at a P/S ratio of 3.4×. Over the past ten years it has ranged from 0.0× (March 2019) to 105× (June 2023); the current reading is higher than 10% of that period. That is below the Biotechnology industry median of 9.4× and in line with the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 3.9× | (64.86%) |
| FY2024 | 11.1× | (75.92%) |
| FY2023 | 46.0× | (43.77%) |
| FY2022 | 81.9× | (14.16%) |
| FY2021 | 95.4× | 134.50% |
| FY2020 | 40.7× | (27.92%) |
| FY2019 | 56.4× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Jun 2026 | 4.2× | 44.49% |
| Mar 2026 | 2.9× | (24.52%) |
| Dec 2025 | 3.9× | (41.20%) |
| Sep 2025 | 6.6× | (19.24%) |
| 23 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| EWTX Edgewise Therapeutics, Inc. compare | n/m |
| DFTX Definium Therapeutics, Inc. compare | n/m |
| ERAS Erasca, Inc. compare | n/m |
| LEGN Legend Biotech Corporation Sponsored ADR | 3.4× |
| TVTX Travere Therapeutics, Inc. compare | 7.2× |
| CRSP CRISPR Therapeutics AG compare | 192× |
| COGT Cogent Biosciences, Inc. compare | 233× |
| RLAY Relay Therapeutics, Inc. compare | 367× |
| DNTH Dianthus Therapeutics, Inc. compare | 1,823× |
| Biotechnology industry median | 9.4× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on LEGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement